GenTrust’s Recursion Pharmaceuticals RXRX Stock Holding History

GenTrust’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.7K	Buy	14,244 +1,807	+15%	+$6.98K	﹤0.01%	280
2025 Q4	$50.9K	Sell	12,437 -2,563	-17%	-$12.7K	﹤0.01%	280
2025 Q3	$73.2K	Hold	15,000	–	–	﹤0.01%	210
2025 Q2	$75.9K	Hold	15,000	–	–	﹤0.01%	175
2025 Q1	$79.3K	Hold	15,000	–	–	﹤0.01%	188
2024 Q4	$101K	Hold	15,000	–	–	﹤0.01%	200
2024 Q3	$98.8K	Hold	15,000	–	–	﹤0.01%	200
2024 Q2	$113K	Hold	15,000	–	–	0.01%	178
2024 Q1	$150K	Hold	15,000	–	–	0.01%	135
2023 Q4	$148K	Hold	15,000	–	–	0.01%	127
2023 Q3	$115K	Buy	+15,000	New	+$150K	0.01%	131

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GenTrust's RXRX Position: Q1 2026 in Review

GenTrust increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, buying an estimated $6.98K and bringing the position to 14,244 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #280.

GenTrust first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $150K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

GenTrust held 14,244 shares of Recursion Pharmaceuticals worth $43.7K as of Q1 2026.
GenTrust bought 1,807 Recursion Pharmaceuticals shares in Q1 2026, an estimated $6.98K.
Recursion Pharmaceuticals made up ﹤0.01% of GenTrust's portfolio in Q1 2026, its #280 holding.
GenTrust first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
GenTrust's Recursion Pharmaceuticals position peaked at $150K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on GenTrust's 13F filing for Q1 2026, filed 27 Apr 2026.